Finger On The Pulse: The State Of Biopharma Leadership

Pharma Leaders Focus On Providing A Clear Vision In The Face Of Uncertainty

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Graphic featuring headshots of all the interviewees
Roivant CEO Matt Gline, UPS Healthcare VP of sales Cathy O'Brien, Pfizer SVP of commercial strategy & innovation Andy Schmeltz, Celltrion USA CEO Tom Nusbickel, Ipsen chief business officer Phillipe Lopes-Fernandes, Sandoz CEO Richard Saynor • Source: Shutterstock

Recent years have seen the role of a biopharma industry leader alter drastically, with events like the COVID-19 pandemic and the war in Ukraine reshaping the day-to-day operations of the sector, from drug distribution to the dominance of remote working. In Vivo caught up with six leaders across the space – from big pharma to generics and biosimilars developers – to get their take on the changing role of a biopharma industry leader.

Matt Gline, CEO of growing biotech company Roivant Sciences Ltd., said: “That’s a hard question and I still spend...

More from Leadership

More from In Vivo

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By 

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.